Methylated Septin 9 as a prognostic factor in colorectal cancer
Recruiting
- Conditions
- C18C20Malignant neoplasm of colonMalignant neoplasm of rectum
- Registration Number
- DRKS00022787
- Lead Sponsor
- niversitätsklinik für Allgemein- Viszeral und Thoraxchiirurgie, Proktologie der RUB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
histological verified colon cancer within stage II-III
histological verified rectal cancer within stage II-III
signed declaration of consent
Exclusion Criteria
patients without complience or patinents who are not able to travel for repetitive examinations to hospital
patients younger than 18 years
pregnant or brestfeeding mothers
secondary carcinomas
patients with chronic gastritis, chronic esophagitis, non rheumatoid arthritis
persons who are to be kept in an institution by judicial or official order
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome of the trial is overallsurvival. It will be determined separately for arm 1 with positive methylation-status at septin9 gene and arm 2 with negative methylation-status at septin9 gene.<br>This survey will be done once a year routinely according to requirements of DKG-certified Darmzentrum. It will be done orally via a questionform and data will be stored at DKG-certified database kolorect.
- Secondary Outcome Measures
Name Time Method overall survival within septin 9 positive patients<br><br>overall survival within septin 9 negative patients<br><br>disease free survival within septin 9 negative patients<br><br>disease free survival within septin 9 positive patients